Cover Image
Market Research Report

Europe PDX Models Market: Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025

Published by Data Bridge Market Research Private Limited Product code 674771
Published Content info 100 Pages
Delivery time: 1-2 business days
Price
Back to Top
Europe PDX Models Market: Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025
Published: July 1, 2018 Content info: 100 Pages
Description

Europe PDX models market was valued at USD 26.95 million in 2017 and growing at a lucrative rate of CAGR in the assessment period. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Prominent factors driving the growth of this market consist of rising number of pharmaceutical R&D activities in cancer research, advantages offered by PDX models offer compared with the classic approach, rising need for personalized medicine and increasing support for cancer research activities from government and non-government organization.

The key market players for Europe PDX models market are listed below:

  • Crown Bioscience Inc.
  • The Jackson Laboratory
  • Champion Oncology, Inc.
  • Charles River
  • Oncodesign
  • Wuxi AppTec
  • Horizon Discovery Group plc
  • Pharmatest Services
  • Hera Biolabs
  • EPO Berlin-Buch GmbH
  • Xentech
  • Urolead
  • Creative Animodel
  • EUROPDX
  • MI Bioresearch Inc
  • Aragen Bioscience

The market is further segmented into:

  • Type
  • Tumor Type
  • Application
  • End User

The Europe PDX models market is segmented based on type into two notable segments; mice models and rat models. In 2018, mice models segment is valued to rule with the highest market share 2025.

The Europe PDX models market is segmented in tumor type categories into six notable segments; respiratory tumor models, urological tumor models, gastrointestinal tumor models, hematological tumor models, gynecological tumor models and others. In 2018, respiratory tumor models segment is valued to rule with the highest market shares by 2025, rising at the highest CAGR.

The Europe PDX models market is segmented in application into preclinical drug development and oncology research and biomarker analysis. In 2018, preclinical drug development and oncology research segment is valued to rule with highest market shares and rising at the highest CAGR.

The Europe PDX models market is segmented in end user into contract research organization (CRO), academic and research institutions and pharmaceutical and biotechnology companies. In 2018, contract research organization (CRO) segment is valued to rule with highest market shares and rising at the highest CAGR.

Based on geography, the market is segmented into:

  • Germany
  • France
  • U.K.
  • Spain
  • Italy
  • Switzerland
  • Netherlands
  • Russia
  • Turkey
  • Belgium
  • Rest of Europe

Covered in this report

The report covers the present scenario and the growth prospects of the Europe PDX models market for 2018-2025. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

TABLE OF CONTENTS

1 INTRODUCTION 11

  • 1.1 OBJECTIVES OF THE STUDY 11
  • 1.2 MARKET DEFINITION 11
  • 1.3 OVERVIEW OF EUROPE PDX MODELS MARKET 11
  • 1.4 CURRENCY AND PRICING 12
  • 1.5 LIMITATION 12
  • 1.6 MARKETS COVERED 12

2 MARKET SEGMENTATION 14

  • 2.1 MARKETS COVERED 14
  • 2.2 GEOGRAPHIC SCOPE 15
  • 2.3 YEARS CONSIDERED FOR THE STUDY 15
  • 2.4 CURRENCY AND PRICING 16
  • 2.5 RESEARCH METHODOLOGY 17
  • 2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 20
  • 2.7 SECONDARY SOURCES 21
  • 2.8 ASSUMPTIONS 21

3 MARKET OVERVIEW 22

  • 3.1 DRIVERS 24
    • 3.1.1 RISING NUMBER OF PHARMACEUTICAL R&D ACTIVITIES IN CANCER RESEARCH 24
    • 3.1.2 PDX MODELS OFFER ADVANTAGES AS COMPARED WITH THE CLASSIC APPROACH 26
    • 3.1.3 RISING NEED FOR PERSONALIZED MEDICINE 27
    • 3.1.4 INCREASING SUPPORT FOR CANCER RESEARCH ACTIVITIES FROM GOVERNMENT AND NON-GOVERNMENT ORGANIZATION 27
  • 3.2 RESTRAINTS 28
    • 3.2.1 HIGH COST OF PDX MODELS 28
    • 3.2.2 STRICT REGULATION WITH RESPECT TO THE UTILIZATION OF ANIMAL MODELS IN CANCER RESEARCH 28
  • 3.3 OPPRTUNITIES 29
    • 3.3.1 INCREASING DEMAND FOR HUMANIZED PDX MODELS 29
  • 3.4 CHALLENGES 30
    • 3.4.1 LIMITATIONS OF PDX MODELS 30

4 EXECUTIVE SUMMARY 31

5 PREMIUM INSIGHTS 33

6 EUROPE PDX MODELS MARKET, BY TYPE 36

  • 6.1 OVERVIEW 37
  • 6.2 MICE MODELS 39
  • 6.3 RAT MODELS 40

7 EUROPE PDX MODELS MARKET, BY TUMOR TYPE 41

  • 7.1 OVERVIEW 42
  • 7.2 GASTROINTESTINAL TUMOR MODELS 44
  • 7.3 GYNECOLOGICAL TUMOR MODELS 45
  • 7.4 RESPIRATORY TUMOR MODELS 46
  • 7.5 UROLOGICAL TUMOR MODELS 47
  • 7.6 HEMATOLOGICAL TUMOR MODELS 48
  • 7.7 OTHERS 49

8 EUROPE PDX MODELS MARKET, BY APPLICATION 50

  • 8.1 OVERVIEW 51
  • 8.2 PRECLINICAL DRUG DEVELOPMENT AND ONCOLOGY RESEARCH 53
  • 8.3 BIOMARKER ANALYSIS 54

9 EUROPE PDX MODELS MARKET, BY END USER 55

  • 9.1 OVERVIEW 56
  • 9.2 CONTRACT RESEARCH ORGANIZATIONS 58
  • 9.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 59
  • 9.4 ACADEMIC AND RESEARCH INSTITUTIONS 60

10 EUROPE PDX MODELS MARKET, BY GEOGRAPHY 61

  • 10.1 EUROPE 61
    • 10.1.1 GERMANY 70
    • 10.1.2 FRANCE 72
    • 10.1.3 U.K. 74
    • 10.1.4 ITALY 76
    • 10.1.5 SPAIN 78
    • 10.1.6 SWITZERLAND 80
    • 10.1.7 NETHERLANDS 82
    • 10.1.8 TURKEY 84
    • 10.1.9 BELGIUM 86
    • 10.1.10 RUSSIA 88
    • 10.1.11 REST OF EUROPE 90

11 EUROPE PDX MODELS MARKET, COMPANY LANDSCAPE 91

  • 11.1 COMPANY SHARE ANALYSIS: EUROPE 91

12 COMPANY PROFILES 92

  • 12.1 CHARLES RIVER 92
    • 12.1.1 COMPANY OVERVIEW 92
    • 12.1.2 REVENUE ANALYSIS 92
    • 12.1.3 COMPANY SHARE ANALYSIS 93
    • 12.1.4 PRODUCT PORTFOLIO 93
    • 12.1.5 RECENT DEVELOPMENTS 93
  • 12.2 CROWN BIOSCIENCE INC. (SUBSIDIARY OF JSR CORPORATION) 94
    • 12.2.1 COMPANY OVERVIEW 94
    • 12.2.2 GEOGRAPHIC PRESENCE 94
    • 12.2.3 COMPANY SHARE ANALYSIS 95
    • 12.2.4 PRODUCT PORTFOLIO 95
    • 12.2.5 RECENT DEVELOPMENTS 96
  • 12.3 CHAMPION ONCOLOGY, INC 97
    • 12.3.1 COMPANY OVERVIEW 97
    • 12.3.2 REVENUE ANALYSIS 97
    • 12.3.3 COMPANY SHARE ANALYSIS 98
    • 12.3.4 PRODUCT PORTFOLIO 98
    • 12.3.5 RECENT DEVELOPMENTS 98
  • 12.4 ARAGEN BIOSCIENCE (SUBSIDIARY OF GVK BIOSCIENCES PRIVATE LIMITED) 99
    • 12.4.1 COMPANY OVERVIEW 99
    • 12.4.2 PRODUCT PORTFOLIO 99
    • 12.4.3 RECENT DEVELOPMENTS 99
  • 12.5 CREATIVE ANIMODEL 100
    • 12.5.1 COMPANY OVERVIEW 100
    • 12.5.2 PRODUCT PORTFOLIO 100
    • 12.5.3 RECENT DEVELOPMENTS 100
  • 12.6 EPO BERLIN-BUCH GMBH 101
    • 12.6.1 COMPANY OVERVIEW 101
    • 12.6.2 PRODUCT PORTFOLIO 101
    • 12.6.3 RECENT DEVELOPMENTS 101
  • 12.7 EUROPDX 102
    • 12.7.1 COMPANY OVERVIEW 102
    • 12.7.2 GEOGRAPHICAL PRESENCE 102
    • 12.7.3 PRODUCT PORTFOLIO 103
    • 12.7.4 RECENT DEVELOPMENTS 103
  • 12.8 HERA BIOLABS 104
    • 12.8.1 COMPANY OVERVIEW 104
    • 12.8.2 PRODUCT PORTFOLIO 104
    • 12.8.3 RECENT DEVELOPMENTS 104
  • 12.9 HORIZON DISCOVERY GROUP PLC 105
    • 12.9.1 COMPANY OVERVIEW 105
    • 12.9.2 REVENUE ANALYSIS 105
    • 12.9.3 PRODUCT PORTFOLIO 106
    • 12.9.4 RECENT DEVELOPMENTS 106
  • 12.10 MI BIORESEARCH INC 107
    • 12.10.1 COMPANY OVERVIEW 107
    • 12.10.2 PRODUCT PORTFOLIO 107
    • 12.10.3 RECENT DEVELOPMENTS 107
  • 12.11 ONCODESIGN 108
    • 12.11.1 COMPANY OVERVIEW 108
    • 12.11.2 REVENUE ANALYSIS 108
    • 12.11.3 PRODUCT PORTFOLIO 109
    • 12.11.4 RECENT DEVELOPMENTS 109
  • 12.12 PHARMATEST SERVICES LTD 110
    • 12.12.1 COMPANY OVERVIEW 110
    • 12.12.2 GEOGRAPHIC PRESENCE 110
    • 12.12.3 PRODUCT PORTFOLIO 111
    • 12.12.4 RECENT DEVELOPMENTS 111
  • 12.13 THE JACKSON LABORATORY 112
    • 12.13.1 COMPANY OVERVIEW 112
    • 12.13.2 REVENUE ANALYSIS 112
    • 12.13.3 PRODUCT PORTFOLIO 113
    • 12.13.4 RECENT DEVELOPMENTS 113
  • 12.14 UROLEAD 114
    • 12.14.1 COMPANY OVERVIEW 114
    • 12.14.2 PRODUCT PORTFOLIO 114
    • 12.14.3 RECENT DEVELOPMENTS 114
  • 12.15 WUXI APPTEC 115
    • 12.15.1 COMPANY OVERVIEW 115
    • 12.15.2 GEOGRAPHIC PRESENCE 115
    • 12.15.3 PRODUCT PORTFOLIO 116
    • 12.15.4 RECENT DEVELOPMENTS 116
  • 12.16 XENTECH 117
    • 12.16.1 COMPANY OVERVIEW 117
    • 12.16.2 PRODUCT PORTFOLIO 117
    • 12.16.3 RECENT DEVELOPMENTS 117

13 RELATED REPORTS 118

LIST OF TABLES

  • TABLE 1 EUROPE PDX MODELS MARKET, BY TYPE, 2016- 2025, (USD MILLION) 38
  • TABLE 2 EUROPE MICE MODELS IN PDX MODELS MARKET, BY REGION, 2016-2025, (USD MILLION) 39
  • TABLE 3 EUROPE RAT MODELS IN PDX MODELS MARKET, BY REGION, 2016-2025, (USD MILLION) 40
  • TABLE 4 EUROPE PDX MODELS MARKET, BY TUMOR TYPE, 2016- 2025 (USD MILLION) 43
  • TABLE 5 EUROPE GASTROINTESTINAL TUMOR MODELS MARKET, BY REGION, 2016-2025, (USD MILLION) 44
  • TABLE 6 EUROPE GYNECOLOGICAL TUMOR MODELS MARKET, BY REGION, 2016-2025, (USD MILLION) 45
  • TABLE 7 EUROPE RESPIRATORY TUMOR MODELS MARKET, BY REGION, 2016-2025, (USD MILLION) 46
  • TABLE 8 EUROPE UROLOGICAL TUMOR MODELS MARKET, BY REGION, 2016-2025, (USD MILLION) 47
  • TABLE 9 EUROPE HEMATOLOGICAL TUMOR MODELS MARKET, BY REGION, 2016-2025, (USD MILLION) 48
  • TABLE 10 EUROPE OTHERS TUMOR TYPES IN PDX MODELS MARKET, BY REGION, 2016-2025, (USD MILLION) 49
  • TABLE 11 EUROPE PDX MODELS MARKET, BY APPLICATION, 2016- 2025 (USD MILLION) 52
  • TABLE 12 EUROPE PRECLINICAL DRUG DEVELOPMENT AND ONCOLOGY RESEARCH IN PDX MODELS MARKET, BY REGION, 2016-2025, (USD MILLION) 53
  • TABLE 13 EUROPE BIOMARKER ANALYSIS IN PDX MODELS MARKET, BY REGION, 2016-2025, (USD MILLION) 54
  • TABLE 14 EUROPE PDX MODELS MARKET, BY END USER, 2016- 2025, (USD MILLION) 57
  • TABLE 15 EUROPE CONTRACT RESEARCH ORGANIZATIONS IN PDX MODEL MARKET, BY REGION, 2016-2025, (USD MILLION) 58
  • TABLE 16 EUROPE PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PDX MODELS MARKET, BY REGION, 2016-2025, (USD MILLION) 59
  • TABLE 17 EUROPE ACADEMIC AND RESEARCH INSTITUTIONS IN PDX MODELA MARKET, BY REGION, 2016-2025, (USD MILLION) 60
  • TABLE 18 EUROPE PDX MODELS MARKET, BY COUNTRY , 2016 - 2025 (USD MILLION) 67
  • TABLE 19 EUROPE PDX MODELS MARKET, BY TYPE, 2016 - 2025, (USD MILLION) 68
  • TABLE 20 EUROPE PDX MODELS MARKET, BY TUMOR TYPE, 2016 - 2025, (USD MILLION) 68
  • TABLE 21 EUROPE PDX MODELS MARKET, BY APPLICATION, 2016 - 2025, (USD MILLION) 69
  • TABLE 22 EUROPE PDX MODELS MARKET, BY END USER, 2016 - 2025, (USD MILLION) 69
  • TABLE 23 GERMANY PDX MODELS MARKET, BY TYPE, 2016 - 2025, (USD MILLION) 70
  • TABLE 24 GERMANY PDX MODELS MARKET, BY TUMOR TYPE, 2016 - 2025, (USD MILLION) 70
  • TABLE 25 GERMANY PDX MODELS MARKET, BY APPLICATION, 2016 - 2025, (USD MILLION) 71
  • TABLE 26 GERMANY PDX MODELS MARKET, BY END USER, 2016 - 2025, (USD MILLION) 71
  • TABLE 27 FRANCE PDX MODELS MARKET, BY TYPE, 2016 - 2025, (USD MILLION) 72
  • TABLE 28 FRANCE PDX MODELS MARKET, BY TUMOR TYPE, 2016 - 2025, (USD MILLION) 72
  • TABLE 29 FRANCE PDX MODELS MARKET, BY APPLICATION, 2016 - 2025, (USD MILLION) 73
  • TABLE 30 FRANCE PDX MODELS MARKET, BY END USER, 2016 - 2025, (USD MILLION) 73
  • TABLE 31 U.K. PDX MODELS MARKET, BY TYPE, 2016 - 2025, (USD MILLION) 74
  • TABLE 32 U.K. PDX MODELS MARKET, BY TUMOR TYPE, 2016 - 2025, (USD MILLION) 74
  • TABLE 33 U.K. PDX MODELS MARKET, BY APPLICATION, 2016 - 2025, (USD MILLION) 75
  • TABLE 34 U.K. PDX MODELS MARKET, BY END USER, 2016 - 2025, (USD MILLION) 75
  • TABLE 35 ITALY PDX MODELS MARKET, BY TYPE, 2016 - 2025, (USD MILLION) 76
  • TABLE 36 ITALY PDX MODELS MARKET, BY TUMOR TYPE, 2016 - 2025, (USD MILLION) 76
  • TABLE 37 ITALY PDX MODELS MARKET, BY APPLICATION, 2016 - 2025, (USD MILLION) 77
  • TABLE 38 ITALY PDX MODELS MARKET, BY END USER, 2016 - 2025, (USD MILLION) 77
  • TABLE 39 SPAIN PDX MODELS MARKET, BY TYPE, 2016 - 2025, (USD MILLION) 78
  • TABLE 40 SPAIN PDX MODELS MARKET, BY TUMOR TYPE, 2016 - 2025, (USD MILLION) 78
  • TABLE 41 SPAIN PDX MODELS MARKET, BY APPLICATION, 2016 - 2025, (USD MILLION) 79
  • TABLE 42 SPAIN PDX MODELS MARKET, BY END USER, 2016 - 2025, (USD MILLION) 79
  • TABLE 43 SWITZERLAND PDX MODELS MARKET, BY TYPE, 2016 - 2025, (USD MILLION) 80
  • TABLE 44 SWITZERLAND PDX MODELS MARKET, BY TUMOR TYPE, 2016 - 2025, (USD MILLION) 80
  • TABLE 45 SWITZERLAND PDX MODELS MARKET, BY APPLICATION, 2016 - 2025, (USD MILLION) 81
  • TABLE 46 SWITZERLAND PDX MODELS MARKET, BY END USER, 2016 - 2025, (USD MILLION) 81
  • TABLE 47 NETHERLANDS PDX MODELS MARKET, BY TYPE, 2016 - 2025, (USD MILLION) 82
  • TABLE 48 NETHERLANDS PDX MODELS MARKET, BY TUMOR TYPE, 2016 - 2025, (USD MILLION) 82
  • TABLE 49 NETHERLANDS PDX MODELS MARKET, BY APPLICATION, 2016 - 2025, (USD MILLION) 83
  • TABLE 50 NETHERLANDS PDX MODELS MARKET, BY END USER, 2016 - 2025, (USD MILLION) 83
  • TABLE 51 TURKEY PDX MODELS MARKET, BY TYPE, 2016 - 2025, (USD MILLION) 84
  • TABLE 52 TURKEY PDX MODELS MARKET, BY TUMOR TYPE, 2016 - 2025, (USD MILLION) 84
  • TABLE 53 TURKEY PDX MODELS MARKET, BY APPLICATION, 2016 - 2025, (USD MILLION) 85
  • TABLE 54 TURKEY PDX MODELS MARKET, BY END USER, 2016 - 2025, (USD MILLION) 85
  • TABLE 55 BELGIUM PDX MODELS MARKET, BY TYPE, 2016 - 2025, (USD MILLION) 86
  • TABLE 56 BELGIUM PDX MODELS MARKET, BY TUMOR TYPE, 2016 - 2025, (USD MILLION) 86
  • TABLE 57 BELGIUM PDX MODELS MARKET, BY APPLICATION, 2016 - 2025, (USD MILLION) 87
  • TABLE 58 BELGIUM PDX MODELS MARKET, BY END USER, 2016 - 2025, (USD MILLION) 87
  • TABLE 59 RUSSIA PDX MODELS MARKET, BY TYPE, 2016 - 2025, (USD MILLION) 88
  • TABLE 60 RUSSIA PDX MODELS MARKET, BY TUMOR TYPE, 2016 - 2025, (USD MILLION) 88
  • TABLE 61 RUSSIA PDX MODELS MARKET, BY APPLICATION, 2016 - 2025, (USD MILLION) 89
  • TABLE 62 RUSSIA PDX MODELS MARKET, BY END USER, 2016 - 2025, (USD MILLION) 89
  • TABLE 63 REST OF EUROPE PDX MODELS MARKET, BY TYPE, 2016 - 2025, (USD MILLION) 90

LIST OF FIGURES

  • FIGURE 1 EUROPE PDX MODELS MARKET: SEGMENTATION 14
  • FIGURE 2 EUROPE PDX MODELS MARKET: DATA TRIANGULATION 17
  • FIGURE 3 EUROPE PDX MODELS MARKET: RESEARCH SNAPSHOT 18
  • FIGURE 4 EUROPE PDX MODELS MARKET : BOTTOM UP APPROACH 19
  • FIGURE 5 EUROPE PDX MODELS MARKET : TOP DOWN APPROACH 19
  • FIGURE 6 EUROPE PDX MODELS MARKET: INTERVIEW DEMOGRAPHICS 20
  • FIGURE 7 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF PDX MODELS MARKET 23
  • FIGURE 8 BELOW MENTIONED IS R&D EXPENSE BY THE JACKSON LABORATORY FOR YEAR 2016-17: 25
  • FIGURE 9 EUROPE PDX MODELS MARKET: SEGMENTATION 32
  • FIGURE 10 RISING NUMBER OF PHARMACEUTICAL R&D ACTIVITIES IN CANCER RESEARCH AND RISING NEED FOR PERSONALIZED MEDICINE ARE EXPECTED TO DRIVE THE MARKET FOR PDX MODELS IN THE FORECAST PERIOD 2018 TO 2025 33
  • FIGURE 11 MICE MODELS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE PDX MODELS MARKET IN 2018 & 2025 34
  • FIGURE 12 ASIA PACIFIC IS THE MAXIMUM GROWING AND MOST PROFITABLE REVENUE POCKETS FOR PDX MODELS MARKET IN THE FORECAST PERIOD FROM 2018 TO 2025 35
  • FIGURE 13 EUROPE PDX MODELS MARKET: BY TYPE, 2017 37
  • FIGURE 14 EUROPE PDX MODELS MARKET: BY TYUMOR TYPE, 2017 42
  • FIGURE 15 EUROPE PDX MODELS MARKET: BY APPLICATION, 2017 51
  • FIGURE 16 EUROPE PDX MODELS MARKET: BY END USER, 2017 56
  • FIGURE 17 EUROPE PDX MODELS MARKET SNAPSHOT (2017) 61
  • FIGURE 18 EUROPE PDX MODELS MARKET: BY COUNTRY (2017) 63
  • FIGURE 19 EUROPE PDX MODELS MARKET: BY COUNTRY (2018 & 2025) 64
  • FIGURE 20 EUROPE PDX MODELS MARKET: BY COUNTRY (2017 & 2025) 65
  • FIGURE 21 EUROPE PDX MODELS MARKET: BY TYPE (2018-2025) 66
  • FIGURE 22 EUROPE PDX MODELS MARKET: COMPANY SHARE 2017 (%) 91
Back to Top